User login
Key clinical point: Spike receptor-binding domain (RBD) immunoglobulin G (IgG) levels following SARS-CoV-2 vaccination were higher in patients with multiple sclerosis (MS) treated with dimethyl fumarate or natalizumab vs. healthy controls; however, the levels were significantly lower in patients receiving sphingosine-1-phosphate receptor modulators (S1P) or anti-CD20 monoclonal antibody (mAb).
Major finding: Postvaccination spike RBD IgG levels were significantly higher in patients treated with dimethyl fumarate (P = .038) and natalizumab (P < .0001) than in healthy controls, whereas patients receiving S1P (P = .01), rituximab (P = .002), or ocrelizumab (P = .0004) showed significantly reduced levels.
Study details: The findings come from a prospective observational study including healthy controls (n = 13) and patients with MS who were either untreated (n = 9) or received treatment with glatiramer acetate (n = 5), dimethyl fumarate (n = 5), natalizumab (n = 6), S1P (n = 7), or anti-CD20 mAbs, including rituximab (n = 13) or ocrelizumab (n = 22).
Disclosures: The study was supported by the National Institutes of Health and others. Some of the authors declared serving on Data Safety Monitoring Boards for or receiving research grant funding and consulting/speaking honoraria from various sources.
Source: Sabatino JJ Jr et al. JCI Insight. 2022 (Jan 14). Doi: 10.1172/jci.insight.156978
Key clinical point: Spike receptor-binding domain (RBD) immunoglobulin G (IgG) levels following SARS-CoV-2 vaccination were higher in patients with multiple sclerosis (MS) treated with dimethyl fumarate or natalizumab vs. healthy controls; however, the levels were significantly lower in patients receiving sphingosine-1-phosphate receptor modulators (S1P) or anti-CD20 monoclonal antibody (mAb).
Major finding: Postvaccination spike RBD IgG levels were significantly higher in patients treated with dimethyl fumarate (P = .038) and natalizumab (P < .0001) than in healthy controls, whereas patients receiving S1P (P = .01), rituximab (P = .002), or ocrelizumab (P = .0004) showed significantly reduced levels.
Study details: The findings come from a prospective observational study including healthy controls (n = 13) and patients with MS who were either untreated (n = 9) or received treatment with glatiramer acetate (n = 5), dimethyl fumarate (n = 5), natalizumab (n = 6), S1P (n = 7), or anti-CD20 mAbs, including rituximab (n = 13) or ocrelizumab (n = 22).
Disclosures: The study was supported by the National Institutes of Health and others. Some of the authors declared serving on Data Safety Monitoring Boards for or receiving research grant funding and consulting/speaking honoraria from various sources.
Source: Sabatino JJ Jr et al. JCI Insight. 2022 (Jan 14). Doi: 10.1172/jci.insight.156978
Key clinical point: Spike receptor-binding domain (RBD) immunoglobulin G (IgG) levels following SARS-CoV-2 vaccination were higher in patients with multiple sclerosis (MS) treated with dimethyl fumarate or natalizumab vs. healthy controls; however, the levels were significantly lower in patients receiving sphingosine-1-phosphate receptor modulators (S1P) or anti-CD20 monoclonal antibody (mAb).
Major finding: Postvaccination spike RBD IgG levels were significantly higher in patients treated with dimethyl fumarate (P = .038) and natalizumab (P < .0001) than in healthy controls, whereas patients receiving S1P (P = .01), rituximab (P = .002), or ocrelizumab (P = .0004) showed significantly reduced levels.
Study details: The findings come from a prospective observational study including healthy controls (n = 13) and patients with MS who were either untreated (n = 9) or received treatment with glatiramer acetate (n = 5), dimethyl fumarate (n = 5), natalizumab (n = 6), S1P (n = 7), or anti-CD20 mAbs, including rituximab (n = 13) or ocrelizumab (n = 22).
Disclosures: The study was supported by the National Institutes of Health and others. Some of the authors declared serving on Data Safety Monitoring Boards for or receiving research grant funding and consulting/speaking honoraria from various sources.
Source: Sabatino JJ Jr et al. JCI Insight. 2022 (Jan 14). Doi: 10.1172/jci.insight.156978